Key validation: dish “survival” correlates with patient survival

1:57:39>> Oh, interesting. >> Do you see what I'm saying? So the patient that I got my donation from of the skin cells that I made my pur potent stem cells from to make into a motor neuron the survival of that >> culture is correlated with the patient him or herself. >> The the the you know the unfortunate point being here is that the real world uh outcome for the patient in terms of time >> is correlated with our ALS in a petri dish. >> Yes. Meaning it is it is replicating >> the problem that the patient had to to a degree that it's it's matching one to one. Exactly. Yeah. And it's unfortunate

1:58:19but at the same time very encouraging because now we have the model >> in our petri dish now we can finally start >> getting to the bottom of how do we fix this? >> Yes. That's that's actually a really really big deal. >> Yeah. >> Um >> and we didn't have this before. >> Yeah. Right. Right. >> Right. This this like we were working with like rats and mice that were just like awful. Right. >> It just didn't work. Right. >> Right. And now we finally got a model. >> We were throwing darts at the board, but the board was behind us. >> Yeah. Exactly. >> You know, it's it's and it's like what are we doing? >> What are we doing? But but the challenge here is again to your point, you know, >> the model the the sort of rodent model works in so many other arenas. It it's fair to have extrapolated it to this

1:58:59one. >> Yeah. Totally. >> But after some time >> Yeah. you're just like, okay, we need something else. >> We need something else. Yeah. This is totally not working. >> Yes. >> Right. >> Yes. >> So here's what they did. They they made a screening library >> 107 commercially available drugs from phase 1 to three ALS trials. So this is pre-clinical. Yes. Right. Um pretty sure, right? Phase 1 to three is is I think pre-clinical. And then 97% of the tested drugs failed. >> Yeah. >> And this is >> sort of exactly what we want, right? That's >> because that's what we're seeing. We're seeing them pass the preclinical and then only when they get to clinical stage in a human being they're failing. Now they're failing in the petri dish. I don't have to waste time and resources

1:59:41like actually doing a clinical trial if it's failing in the petri dish. >> So that's the whole point >> just to say it back to you. We took what was working in pre-clinical before but failing in humans. We took our petri dish platform. >> We applied the already commercially available options and 97% of them failed in our petri dish. when they were passing in the pre-clinical in the prior regime. Yeah. And so the point here is is the again not only are we seeing in patients this the the the one to one on survival time we are also seeing a onetoone on efficacy in testing in this sort of pre-trial

2:00:22environment in in this in lab environment. Yeah. >> Not even in the in lab. >> Yeah. Meaning we can feel we can have some level of confidence